{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "2879832",
  "DateCompleted": {
    "Year": "1987",
    "Month": "02",
    "Day": "27"
  },
  "DateRevised": {
    "Year": "2013",
    "Month": "11",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0160-6689",
      "JournalIssue": {
        "Volume": "48",
        "Issue": "1",
        "PubDate": {
          "Year": "1987",
          "Month": "Jan"
        }
      },
      "Title": "The Journal of clinical psychiatry",
      "ISOAbbreviation": "J Clin Psychiatry"
    },
    "ArticleTitle": "Effect of clorazepate on depressed mood in anxious patients.",
    "Pagination": {
      "StartPage": "13",
      "EndPage": "14",
      "MedlinePgn": "13-4"
    },
    "Abstract": {
      "AbstractText": [
        "A double-blind, placebo-controlled study of clorazepate in the treatment of 189 patients diagnosed with generalized anxiety disorder was conducted to evaluate the efficacy of an anxiolytic on the depressed-mood component of anxiety. Clorazepate-treated patients with concomitant high levels of depressed mood, defined as a score of 60 or above on the Zung Self-Rating Depression Scale (SDS), showed significant improvement of anxiety symptomatology, as measured by the Hamilton Rating Scale for Anxiety and the Zung Self-Rating Anxiety Scale, and of depressed mood, as measured by the SDS, compared with placebo-treated patients (all p values less than .01)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Zung",
        "ForeName": "W W",
        "Initials": "WW"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Controlled Clinical Trial",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Clin Psychiatry",
    "NlmUniqueID": "7801243",
    "ISSNLinking": "0160-6689"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Placebos"
    },
    {
      "RegistryNumber": "63FN7G03XY",
      "NameOfSubstance": "Clorazepate Dipotassium"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Anxiety Disorders"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Clorazepate Dipotassium"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Personality Inventory"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Placebos"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychiatric Status Rating Scales"
    }
  ]
}